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Cancer of the kidney is associated with a bewil-
dering array of extrarenal symptoms, and conversely, 
tumors far removed from the kidney produce in-
triguing renal functional abnormalities. 
A variety of extrarenal complications are seen 
with hypernephromas, most of which rarely accom-
pany Wilms tumors which grow rapidly and generally 
occur before the age of 7. Wilms tumors are quite 
susceptible to radiation therapy and surgery, and are 
to be strongly suspected when hypertension and an 
abdominal mass are found in a small child. Unless 
treated, they rapidly cause death and usually leave 
little opportunity for the patient to develop the strik-
ing extrarenal manifestations seen with hyper-
nephroma. 
Among the fascinating complications of hyper-
nephromas (Table l) is first, the extremely slow 
growth rate of a sizable minority of them. I have seen 
patients known to have hematuria for up to three 
years prior to the time that the tumor was found and, 
on reviewing the intravenous pyelogram done at the 
onset of hematuria, seen evidence that a renal mass 
had been present all along. Those tumors which do 
grow slowly may result in generalized amyloidosis 
both in the kidney and elsewhere. Another peculiarity 
of the hypernephroma, which is almost unique to this 
tumor, is the disappearance of metastases once the 
primary tumor has been removed. In only a few 
instances has there been histologic evidence that the 
"metastatic" lesions were indeed derived from a renal 
cell carcinoma. Nevertheless, the phenomenon of 
spontaneous regression of metastases seems well es-
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tablished and offers at least a gleam of hope for those 
in whom pulmonary metastases are found . 
Perhaps equally remarkable is the finding of dis-
tant metastases many years after a renal cell carci-
noma is removed surgically . The longest recorded 
survival between a diagnosis of renal carcinoma and 
the eventual death of a patient whose neoplasm was 
considered inoperable and left in place is 37 years. 1 
Many patients have been reported to develop metas-
tases 5, JO, and even 25 years after the resection of a 
hypernephroma. I have seen a patient who developed 
"solitary" metastases sequentially over a 19-year pe-
riod before he succumbed. Unfortunately, while such 
cases stand out, metastases appear earlier in most 
patients and lead to death within two years in one 
third of patients. 
Renal cell carcinoma also tends to extend via the 
renal vein lumen into the inferior vena cava. Such a 
circumstance is reported to occur in almost 10% of 
patients with hypernephromas,2 and a substantial 
proportion of these tumors extends all the way up the 
vena cava into the right atrium.3 The extending tu-
mor usually is restricted to the venous lumen without 
penetration of the vessel wall and, as a result, is 
generally removable in its entirety. Surprisingly, such 
vascular involvement a lone does not appear greatly 
to alter the prognosis at 5 or l O years,4 and extraction 
of the tumor mass is often both possible and desir-
able. 
Fever, unexplained by infection, is a common 
concomitant of hypernephroma. Melicow and Uson~ 
have reported that 16% of 577 cases of renal carci-
noma presented with fever, often with weakness, ano-
rexia, and weight loss, without any urologic symp-
toms whatsoever. A much higher percentage 
combined these systemic manifestations with hema-
turia, an abdominal mass, or pain . Thus, it is not 
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TABLE I 
Peculiarities of Hypernephromas 
1. Slow growth frequent 
2. Disappearance of metastases (rare) 
3. Cause of occult fever (FUO) 
4. Renal vein/ vena cava spread 
5. Nonmetastatic hepatic dysfunction 
6. Benign nephrohepatomegaly 
7. Polycythemia, leukemoid reaction , eosinophilia 
8. Heart fai'lure 
9. Spontaneous rupture of kidney 
uncommon for patients with hypernephroma to pres-
ent with "fever of unknown origin" and a baffling 
clinical picture. The fever may be low-grade and con-
stant or intermittent and hectic, temperatures reach-
ing 39.5 C (103 F) and higher. 
First described in 1961,6 a syndrome of non-
metastatic hepatic dysfunction (NHDS) accompanies 
the systemic abnormalities mentioned above in some 
10% of patients with hypernephromas,7 and presents 
with hepatomegaly which differs both functionally 
and histologically from the benign hepatomegaly fre-
quently encountered with such tumors.a Here, bio-
chemical abnormalities include elevated serum alka-
line phosphatase concentrations, hypoalbuminemia, 
and hyperglobulinemia. Liver biopsy may reveal non-
specific inflammatory infiltrates, fatty deposition, de-
generative and regenerative changes of liver cells, and 
areas of focal necrosis.a The syndrome may mimic 
metastatic disease of the liver from which it must be 
distinguished in that it is potentially reversible after 
nephrectomy is performed; recognition of NHDS 
may suggest a diagnosis of previously unrecognized 
hypernephroma. 
Reviews of polycythemia generally include hy-
pernephroma in the list of causes, but in fact, poly-
cythemia has been associated with this tumor in only 
1% to 4% of most reported series. 10 Actually, anemia 
is more the rule than the exception whether or not the 
patient has had significant hematuria. 11 Eosinophilia, 
thrombocytosis, leukocytosis, and even leukomoid 
reactions occur in significant association with hyper-
nephromas.12 Coupled with fever of unknown origin, 
or alone, such findings may present vexing diagnostic 
problems. 
As in many other types of malignancy, throm-
bophlebitis accompanies renal cell carcinoma with 
some frequency. Varicocele, particularly when on the 
right, may be the first clue to the existence of a renal 
tumor. 
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Hypertension is recorded in more than 20% of 
the patients with hypernephroma and in some cases, 
at least, the hypertension has been cured by nephrec-
tomy .5 In others, hypertension is not surgically cor-
rectable, and it is difficult to be sure that the tumor 
was causally related. The renal tumor most clearly 
associated with hypertension is the "juxtaglomerular 
cell" tumor. Neoplastically benign, this growth, orig-
inating in macula densa tissue, produces huge 
amounts of renin with resultant secondary hyper-
aldosteronism and the complications attendant upon 
that condition. It is mentioned here as a rare but 
fascinating renal tumor which produces signs and 
symptoms which may erroneously suggest the exis-
tence of renal arterial stenosis or venous obstruction 
secondary to the spread of renal adenocarcinoma or 
the hyperreninism sometimes associated with Wilms 
tumors.13 
Uncommon but life-threatening vascular com-
plications of hypernephromas include high-output 
congestive heart failure and spontaneous rupture of 
the kidney with hemorrhagic shock. Heart failure is 
attributable to highly vascular metastases with arte-
riovenous communications analogous to those ob-
served in Paget disease. 14 Spontaneous rupture pro-
duces massive retroperitoneal hemorrhage closely 
resembling a ruptured aortic aneurysm and is equally 
lethal. 15 
Renal Complications of Extrarenal Malignancies 
Space does not permit a detailed discussion of 
the many abnormalities of renal function found in 
subjects with malignant diseases; however, I shall 
comment upon the fluid and electrolyte disorders 
which frequently occur (Table 2), and discuss the 
nephrotic syndrome associated with malignancy. 
Hypercalcemia may result from bony metastases 
or the forced immobilization of acutely ill patients. 
Certain cases are the result of parathormone secreting 
tumors which function autonomously, 16 and a grow-
ing number of reports have called attention to the 
existence of prostaglandin-secreting tumors produc-
ing hypercalcemia which may be reversed with indo-
methacin.17 The hypercalcemia caused by both hor-
mone-secreting tumors is reversible with complete 
removal of the tumor. Persistence of hypercalcemia 
after the primary tumor is excised may reflect the 
other causes of hypercalcemia (see Table 2 ), or be the 
result of metastases which, like the parent tumor, also 
synthesize prostaglandins or parathormone. 
Hypercalcemia, if severe, may have devastating 
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TABLE 2 
Electrolyte Abnormalities with Nonrenal Malignancies 
I. HYPERCALCEMIA-producing severe volume depletion and functional renal failure , nephrolithiasis or nephrocalcinosis: 
a. Metastases 
b. Corticosteroid withdrawal/adrenal insufficiency 
c. Prostaglandin-secreting tumors 
d. Forced immobilization 
e. Parathormone-secreting tumors 
2. VOLUME DEPLETION AND HYPONATREMIA •-producing functional renal failure: 
a . Hypoadrenalcorticism of tumor replacement, amyloidosis, surgical ablation of the adrenals, disseminated intra vascular coagulation 
(DIC). 
b. Excessive diuretic therapy for peritoneal metastases or mechanical edema. 
c. Rapidly developing ascites and edema 
d. Extrarehal electrolyte losses:secretory diarrheas, villous a denomas , drug Rx hyperemesis, intestinal obstruction, malabsorption and 
carcinoid. 
• To be distinguished from the syndrome of inappropriate ADH secretion (CNS tumor/ metastases, vasopressin-secreting tumors, 
vincristine/ cyclophosphamide therapy, and tricyclic anticonvulsants) where renal function does not specifically become impaired. 
3. VOLUME DEPLETION AND HYPERNATREMIA-with functional renal failure: 
a. Diabetes insipidus of pituitary replacement, brain metastases, urinary outflow obstruction. 
b. Impaired thirst mechanism-organic or functional results of cachectic illness. 
c. Kaliopenic and hypercalcemic nephropathy 
d . Nasogastric feeding-osmotic diuresis 
4. KALIOPENIC NEPHROPATHY-with impaired concentrating capacity and susceptibility to pyelonephritis: 
a. Pernicious gastrointestinal electrolyte loss (see section 2) 
b. " ACTH"-producing tumors 
c. Juxtaglomerular cell tumors 
d. Improper diuretic therapy 
e. Lysozymuric and nonlysozymuric leukemias 
effects upon the kidney, producing severe volume 
depletion and functional renal failure, nephrolithiasis 
with infection and urinary outflow obstruction, or 
severe tubulointerstitial disease due to nephrocalci-
nos1s. 
Volume depletion and hyponatremia are fre-
quent complications which plague the patient with 
malignant disease. Generically, the concurrence of 
volume depletion and hyponatremia reflects a state in 
which both sodium and water are lost from the body 
in large amounts but the net sodium loss exceeds the 
water deficit. Causes include adrenal insufficiency 
owing to tumor replacement, adrenal amyloidosis, 
surgical ablation of the adrenals as a therapeutic 
adjuvant, and disseminated intravascular coagu-
lation. Ill-advised sodium restriction with vigorous 
diuretic therapy in an attempt to minimize mechani-
cal edema or ascites due to peritoneal metastases is a 
reasonably common cause of hyponatremic volume 
depletion. The rapid development of ascites and 
edema in sodium-restricted patients is another cause. 
Massive electrolyte losses may occur through the in-
testinal tract as a result of the hyperemesis associated 
with cancer chemotherapy, the secretory diarrheas 
[amine precursor uptake and decarboxylation 
(APUD) syndromes], mucus-secreting intestinal 
tumors, intestinal obstruction, or malabsorption. 
Massive fluid losses may be seen in the carcinoid 
syndrome. The severe volume depletion .attendant 
upon these complications may produce major abnor-
malities in renal function unless corrected. 
Hyponatremia may also be seen in the presence 
of extracellular fluid volume expansion-the so-
called syndrome of inappropriate antidiuretic hor-
mone (ADH) secretion. Causes include vasopressin-
secreting tumors (especially of lung), primary or 
metastatic intracranial malignancies, vincristine or 
cyclophosphamide therapy to retard tumor growth, 
and \he tricyclic anticonvulsants .18 
Volume depletion may coexist with hyper-
natremia for a variety of reasons. Diabetes insipidus 
may result from tumor invasion of the pituitary 
gland, intracranial metastases, or urinary outflow ob-
struction. Nasogastric feeding of concentrated solu-
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tions lacking in free water is a common cause of an 
obligatory solute diuresis. Impaired thirst due to ei-
ther organic brain disease or as a functional result of 
a cachectic illness may contribute greatly to the devel-
opment of hypernatremic volume depletion, a situa-
tion which is further aggravated if kaliopenic or hy-
percalcemic nephropathy is present. 
Kaliopenic (hypokalemic) nephropathy is mani-
fested by impaired concentrating capacity and an 
increased susceptibility to pyelonephritis. It may re-
sult from pernicious gastrointestinal electrolyte 
losses, hyperadrenal corticism secondary to an ad-
renocorticotropic hormone (ACTH)-producing tu-
mor, juxtaglomerular cell tumors, or improper diu-
retic management. Major degrees of hypokalemia 
may be seen in patients with leukemia, especially 
those leukemias associated with lysozymuria. 19 Im-
paired concentrating capacity may well lead to seri-
ous volume depletion and secondary renal dysfunc-
tion. 
Nonelectrolyte-related abnormalities of the uri-
nary tract are listed in Table 3, but cannot be covered 
in detail in this brief review. 
Nephrotic Syndrome Associated with Malignancy 
An increasing number of reports amply docu-
ment the association of the nephrotic syndrome with 
TABLE 3 
Nonelectrolyte Renal Complications of Malignancies 
I. Fanconi syndrome 
2. Renal tubular acidosis 
3. Hydronephrosis-obstructive renal failure 
4. Renal amyloidosis 
5. Urate nephropathy 
6. Radiation nephritis 
7. "Citrovorum rescue," antimetabolite nephropathy 
8. Myeloma kidney 
9. Renal hemorrhage, outflow obstruction 
JO. Cortical necrosis post-disseminated intravascular coag-
ulation (DIC) 
11 . Tumor-related lupus erythematosus (especially with 
lymphoma ) 
12. Renal vein/ arterial or vena caval occlusion 
13. Vasomotor nephropathy-hemorrhage, sepsis, shock, 
and so forth 
14. Nephrolithiasis/ nephrocalcinosis 
15. Obstruction of bladder outflow, ureters, or urethra by 
tumor invasion 
16. Renal invasion by metastases 
17. Benign nephromegaly, etiology unknown 
18. Retroperitoneal fibrosis/ tumor invasion, producing 
ureteral obstruction 
19. Nephrotic syndrome 
20. Acute papillary necrosis, pyelonephritis 
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malignant tumors.20 Some cases are the result of 
amyloidosis, others to renal venous outflow obstruc-
tion, and still others to probable immune mecha-
nisms. Myeloma and lymphoproliferative disorders are 
among the most common tumor-related causes of 
amyloidosis, yet solid tumors also may cause amyloid 
deposition if their course is not an accelerated one.22 
Invasion of the renal veins and vena cava by hyper-
nephromas or other tumors, and compression of 
venous structures by retroperitoneal nodes, tumor 
mass, or retroperitoneal fibrosis may produce me-
chanical edema and marked proteinuria but are un-
common causes of the nephrotic syndrome. 
Tumor-related nephrotic syndrome occurs with 
some frequency in the absence of either amyloidosis 
or venous obstruction, Hodgkin disease leading the 
list of causes.21 Lymphosarcoma, chronic lymphocy-
tic leukemia, and Burkitt lymphoma also have been 
associated with frank nephrosis.21 Of the solid tu-
mors, bronchogenic carcinoma has been the most 
often found. Malignancies of the stomach, colon, 
breast, skin, ovary, oropharynx, and kidneys have 
all been incriminated. 
The majority of lymphoma-related cases have 
shown minimal glomerular changes on biopsy or 
postmortem study. Most other types of tumors have 
produced membranous, proliferative or mixed mem-
branous and proliferative lesions. Reversal of the 
nephrotic syndrome after excision or chemotherapy 
of the primary tumor has been observed by many 
authors, the return of proteinuria signaling regrowth 
of the malignancy 21 
In this overview, I have tried to touch on the 
highly complex interaction between carcinomatosis 
and the kidney. The manifestations of this relation-
ship are so diverse and numerous that it is well to 
remember the adage, "Many a medical reputation 
has been lost in the retroperitoneum." It is hoped 
that continued awareness of the protean manifesta-
tions of tumors relating to the kidney will help to 
preserve the reputations of all clinicians. 
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